Available Vs the Courts Version

The Prizes CP claims to solve the Takings Advantage. Instead of altering sovereign immunity, the CP says that the government should give monetary prizes to the companies that have the best/most significant pharmaceutical and life sciences innovation, which claims to solve competition without altering IP.

The Fair Use DA argues that overturning the ASTM case would shift how the courts view Fair Use, which would have negative implications for OpenAI in its upcoming suit against the New York Times: OpenAI vs. New York Times. This DA is a net benefit to all of the CPs.